A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Inavolisib in Combination with Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors

2023-506745-33-00 Protocol CO42800 Human pharmacology (Phase I) - Other Ended

Start 12 Jul 2021 · End 13 Jan 2026 · Status Ended · 3 EU/EEA countries · 6 sites · Protocol CO42800

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 106
Countries 3
Sites 6

Locally Advanced or Metastatic Solid Tumors

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
12 Jul 2021 → 13 Jan 2026
Decision date (initial)
2024-06-12
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-506745-33-00
EudraCT number
2020-005057-24

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Locally Advanced or Metastatic Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

3 EU/EEA countries · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ended 10 1
France Ended 8 2
Spain Ended 12 3
Rest of world
Canada, United States, Korea, Republic of, Brazil
76

Investigational sites

Denmark

1 site · Ended
Rigshospitalet
Fase 1 Enhed - Onkologi, Blegdamsvej 9, 2100, Copenhagen Oe

France

2 sites · Ended
Institut Bergonie
Oncologie, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Centre Leon Berard
Departement de medecine, 28 Rue Laennec, 69008, Lyon

Spain

3 sites · Ended
Hospital Universitari Vall D Hebron
Servicio de Oncología, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital Clinico Universitario De Valencia
Servicio de Oncología, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Hm Sanchinarro
Servicio de Oncología, Calle Ona 10, 28050, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2021-10-04 2022-02-02 2025-02-25
France 2021-09-17 2026-01-13 2021-11-21 2025-02-25
Spain 2021-07-12 2025-06-19 2021-07-14 2025-02-25

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-10 Denmark Acceptable
2024-06-12
2024-06-12
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-20 Denmark Acceptable
2024-11-29
2024-11-29
3 SUBSTANTIAL MODIFICATION SM-2 2025-03-21 Denmark Acceptable
2025-05-05
2025-05-05
4 SUBSTANTIAL MODIFICATION SM-3 2025-10-27 Acceptable
2025-12-15
2026-01-06